Showing 2623 results
- https://www.novartis.com/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
- https://www.novartis.com/news/media-releases/sandoz-advances-its-biosimilars-program-ema-acceptance-regulatory-submission-biosimilar-pegfilgrastimSandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
- https://www.novartis.com/news/in-the-news/novartis-flipping-pyramid-explains-steven-baertIn this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and…
- https://www.novartis.com/news/in-the-news/fortunes-most-admired-pharmaceutical-companies-2019Novartis ranks #4 in Fortune Magazine’s Most Admired Companies Pharmaceutical Industry list.
- https://www.novartis.com/news/in-the-news/science-and-business-innovative-medicinesIn this a16z podcast, bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis, on some questions, challenges and opportunities that we’re facing…
- https://www.novartis.com/news/in-the-news/how-long-till-final-world-malaria-dayDeaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could…
- https://www.novartis.com/news/in-the-news/novartis-access-and-government-cameroon-sign-agreement-fight-chronic-diseasesCameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable…
- https://www.novartis.com/news/in-the-news/changing-worldNovartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based…
- https://www.novartis.com/news/in-the-news/increasing-access-ncd-treatments-ugandaNovartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
- https://www.novartis.com/news/in-the-news/novartis-access-and-government-pakistan-sign-memorandum-understandingNovartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page